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Design: Double-blind, randomized administration of two 12-week courses of ulipristal acetate.
Setting: Gynecology centers.
Patient(s): A total of 451 patients with symptomatic uterine ﬁbroid(s) and heavy bleeding.
Intervention(s): Two repeated 12-week treatment courses of daily 5 or 10 mg of ulipristal acetate.
Main Outcome Measure(s): Amenorrhea, controlled bleeding, ﬁbroid volume, quality of life (QoL), pain.
Result(s): In the 5- and 10-mg treatment groups (62% and 73% of patients, respectively) achieved amenorrhea during both treatment
courses. Proportions of patients achieving controlled bleeding during two treatment courses were >80%. Menstruation resumed after
each treatment course and was diminished compared with baseline. After the second treatment course, median reductions from baseline
in ﬁbroid volume were 54% and 58% for the patients receiving 5 and 10 mg of ulipristal acetate, respectively. Pain and QoL improved
in both groups. Ulipristal acetate was well tolerated with less than 5% of patients discontinuing treatment due to adverse events.Received September 17, 2014; revised and accepted October 21, 2014; published online December 24, 2014.
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ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEConclusion(s): Repeated 12-weekcourses ofdaily oral ulipristal acetate (5 and10mg) effectively control bleedingandpain, reduceﬁbroidUse your smartphonevolume, and restore QoL in patients with symptomatic ﬁbroids.
Clinical Trial Registration Number: NCT01629563 (PEARL IV). (Fertil Steril 2015;103:
519–27. 2015 by American Society for Reproductive Medicine.)
Key Words: Repeated intermittent use, ulipristal acetate, uterine ﬁbroid, quality of life,
long-term treatment
Discuss: You can discuss this article with its authors and with other ASRM members at http://
fertstertforum.com/donnezj-ulipristal-acetate-uterine-ﬁbroids/to scan this QR code
and connect to the
discussion forum for
this article now.*
* Download a free QR code scanner by searching for “QR
scanner” in your smartphone’s app store or app marketplace.U terine leiomyomas, or ﬁbroids, occur in 20%–40% ofwomen of reproductive age (1). The most commonsymptoms are heavy menstrual bleeding, pain,
dysmenorrhea, pelvic pressure, and anemia, resulting in
chronic fatigue that adversely affects the women's quality
of life and fertility (2).
Surgical and other invasive interventions still dominate
treatment (3). Medical therapy is currently limited to preoper-
ative reduction of symptoms related to uterine bleeding and
ﬁbroid size (4, 5) with no medical therapy providing long-
term efﬁcacy and acceptable tolerability and safety (4–11).
Ulipristal acetate (5 mg) once daily dose is approved in
Europe and Canada for preoperative ﬁbroid treatment (12).
Ulipristal acetate, a selective P receptor (PR) modulator with
pharmacokinetic properties supporting once daily dosing
(13) potently modulates PR activity without suppressing
E2 to postmenopausal levels, and shows proapoptotic/antipro-
liferative effects on ﬁbroid cells (13–17). Several short-term
(3 months) randomized clinical studies showed that ulipristal
acetate effectively controls bleeding and shrinks ﬁbroids
(18–21). After treatment cessation, return of menstruation
usually occurs within 4–5 weeks but ﬁbroid volume
reduction can be sustained for up to 6 months. In addition,
treatment with ulipristal acetate improved quality of life,
reduced ﬁbroid-associated pain, and revealed no safety con-
cerns (20, 21). A selective PR modulator administration has
been shown in clinical studies to lead to a pattern of benign,
nonphysiological, nonproliferative, histologic features of the
endometrium termed Progesterone receptor modulator
Associated Endometrial Changes (PAEC) (22–25). These
changes spontaneously reverse a few weeks to months after
the end of ulipristal acetate treatment (20, 21, 26). Hence,
intermittent courses of 12-week ulipristal acetate treatment
with off-treatment intervals are a potential option for the
long-term medical management of ﬁbroids (12). Another
open-label clinical study indicated that repeated use of ulipris-
tal acetate (10 mg/d) for four 12-week consecutive treatment
courses could achieve control of uterine bleeding and pain,
ﬁbroid volume reduction, and restore quality of life (26). The
study design allowed for subjects to choose whether to com-
plete only one treatment course before surgery or to continue,
leading to a substantial reduction in patient numbers between
the ﬁrst and second treatment courses.
We conducted the study PGL4001 (ulipristal acetate) Efﬁ-
cacy Assessment in Reduction of symptoms due to uterine
Leiomyomata (PEARL IV) to evaluate the efﬁcacy and safety520of repeated 12-week courses of daily 5- or 10-mg doses of
ulipristal acetate.
The primary null hypothesis for this study was that there
would be no difference in the percentage of subjects who were
in amenorrhea at the end of both treatment courses 1 and 2 for
10 mg of ulipristal acetate compared with 5 mg of ulipristal
acetate.
MATERIALS AND METHODS
Study Design and Oversight
PEARL IV was a Phase III multicenter, randomized, double-
blind, parallel group, long-term study investigating the efﬁ-
cacy and safety of 5 and 10 mg doses of ulipristal acetate
for the treatment of uterine ﬁbroids. PEARL IV was conducted
in 46 study sites across 11 countries from June 2012 to
February 2014. The study was approved by the independent
ethics committee at each participating site and was conducted
in accordance with the International Conference on
Harmonization-Good Clinical Practice guidelines. The study
was designed by the sponsor (PregLem) with the involvement
of academic investigators and a study statistician. Data were
collected by an independent contract research organization
(ICON Clinical Research), and handled and analyzed by an in-
dependent data management organization (CROS NT). Jac-
ques Donnez vouches for the data accuracy and analysis,
and the ﬁdelity of the study to the protocol. We present the
results of part I on the ﬁrst two treatment courses.Study Population
We enrolled premenopausal women with at least one ﬁbroid
R3 cm in diameter and none>12 cm, as assessed by ultraso-
nography. Heavy menstrual bleeding (pictorial blood-loss
assessment chart [PBAC]) score >100 and uterine size
<16 weeks of gestation were calculated. Eligible women
were aged between 18 and 50 years inclusive, with a body
mass index (BMI) of 18–40 (kg/m2) and regular menstrual cy-
cles of 22–35 days with FSH %20 IU/L. Written informed
consent was obtained from all women. The main exclusion
criteria are listed in Supplemental Table 1 in the Appendix
(available online).Randomization and Intervention
Women were allocated randomly by a web-integrated
voice response system in a 1:1 ratio to receive either 5 orVOL. 103 NO. 2 / FEBRUARY 2015
Fertility and Sterility®10 mg/d of oral ulipristal acetate and matching placebos for
two 12-week courses. Ulipristal acetate was started during
the ﬁrst 4 days of menstruation. Treatment courses were sepa-
rated by a drug-free interval. The second course was
commenced with the second off-treatment menstruation. Af-
ter the second treatment course and subsequent menstruation,
an end of part I visit was performed. The sequence of visits,
treatments and biopsies illustrated in Appendix,
Supplemental Figure 1 and Supplemental Table 2 (available
online).Assessment of Uterine Bleeding
Patients recorded their bleeding pattern in a diary using an 8-
day PBAC (27, 28) at screening and during the ﬁrst
menstruation after each treatment course. A PBAC score
of >100 indicates menorrhagia. Bleeding pattern outside of
the time frame was recorded in a diary with a simpliﬁed
semiquantitative questionnaire containing four categories
deﬁned as ‘‘no bleeding,’’ ‘‘spotting,’’ ‘‘bleeding,’’ or ‘‘heavy
bleeding.’’ Patients were asked to record their bleeding daily
from start of treatment to the end of the observation visit.Assessment of Endometrial Histology
Endometrial biopsies were obtained at screening and after
treatment course 2 (10–18 days after start of menses for
both treatment courses). An additional biopsy was performed
during treatment course 1 if the screening biopsy was inade-
quate. All biopsies were assessed by three independent pa-
thologists blinded to visit sequence, study group
assignment, and each other's assessments.Assessment of Fibroid Size and Endometrial
Thickness
Fibroid and endometrial thickness measurements were carried
out by transvaginal ultrasound at screening, post-treatment
course 1 (10–18 days after start of menses), at the end of treat-
ment course 2, and after treatment course 2 (10–18 days after
start of menses for both treatment courses).End Points
The primary efﬁcacy end point was the percentage of patients
in amenorrhea at the end of both treatment courses. Amenor-
rhea was deﬁned as no more than 1 day of spotting within a
35-day interval.
Secondary efﬁcacy end points included amenorrhea at
the end of each treatment course and the last 56 days of
each treatment course, controlled bleeding at the end of
both courses and each treatment course individually (deﬁned
as no episodes of heavy bleeding and a maximum of 8 days of
bleeding during the last 56 days of a treatment course), time to
amenorrhea at the start of each individual treatment course,
volume of three largest ﬁbroids, and uterus (measured by
transvaginal ultrasound), pain, and quality of life.
The safety end points included number and proportion of
patients withdrawing from treatment early for safety reasons,
number and proportion of patients experiencing adverseVOL. 103 NO. 2 / FEBRUARY 2015events including clinically signiﬁcant changes in gynecolog-
ical or breast examination, ovarian ultrasound, electrocardio-
gram, laboratory parameters, vital signs, and endometrial
histology.Statistical Analysis
Efﬁcacy analyses were based on the full analysis set, deﬁned
as all randomized and treated patients. All statistical tests
were two-sided, with a 5% level of signiﬁcance. No adjust-
ments were made for the multiple testing of secondary end
points. In general, missing values were not imputed before
analysis. However, if 3 consecutive days or less of the daily
bleeding pattern were missing, the missing values were
imputed with the greatest strength of bleeding immediately
before or after the period of missing days.
The results for binary end points (including the primary
efﬁcacy end point) for 10 mg of ulipristal acetate versus
5 mg of ulipristal acetate were compared using c2 tests,
with conﬁdence intervals of the difference calculated using
the Newcombe-Wilson score method (29). The change in total
ﬁbroid volume and uterine volume were analyzed by
repeated-measures analysis of covariance after a log-
transformation, with the results back-transformed before pre-
sentation. The change from baseline in PBAC scores was
analyzed by the Wilcoxon rank sum test with the Hodges-
Lehmann estimator (and corresponding Moses conﬁdence in-
terval) used for the differences in medians (30).
Assuming a dropout rate of approximately 10%, we esti-
mated that 444 patients should be randomized for the study to
have a power more than 85% to detect an absolute difference
in the primary end point of 14% or more.
RESULTS
Patients
Demographic and baseline characteristics were balanced
among the two treatment groups (Table 1). All patients had
moderate-to-severe bleeding, and many had considerable
pain, as well as impaired quality of life (Table 1). More than
90% patients completed both treatment courses. Adverse
events (21 patients) and lack of efﬁcacy (3 patients) were
infrequent causes of study discontinuation (Appendix and
Supplemental Fig. 2, available online).Efﬁcacy
Menstrual bleeding. In the 5- and 10-mg treatment groups
(62% and 73% patients, respectively) achieved amenorrhea at
the end of both treatment courses (P¼ .03; Table 2). Rates of
amenorrhea after each individual treatment coursewere higher
for patients receiving 10 mg (83%) than 5 mg (72%–74%)
(Supplemental Table 3 in the Appendix, available online) The
median times to amenorrhea after the start of each treatment
course were%6 days for each treatment group (Table 2). The
proportions of patients with controlled bleeding at the end of
both treatment courseswere>80%,withno statistically signif-
icant differences between treatment groups (Table 2).
Menstruation resumed in most patients after the end of
each treatment course within a median time of %28 days.521
TABLE 1
Baseline characteristics (full analysis set).
Characteristic Ulipristal acetate 5 mg (N[ 228) Ulipristal acetate 10 mg (N[ 223)
Age (y), mean (SD) 41.6 (5.4) 41.1 (5.1)
Ethnicity, n (%)
Caucasian 211 (92.5) 214 (96.0)
Black 12 (5.3) 8 (3.6)
Other 4 (1.8) 1 (0.4)
Not reported 1 (0.4) 0
Weight (kg), mean (SD) 69.2 (12.7) 70.0 (12.8)
BMI (kg/m2), mean (SD) 25.2 (4.1) 25.3 (4.5)
PBAC Score, median (IQR) 224 (148–357) 215 (151–373)
Total volume of three largest ﬁbroids (cm3), median (IQR) 42.6 (24.0–94.2) 43.6 (27.3–117.3)
Uterine volume (cm3), median (IQR) 176.9 (113.1–269.8) 175.22 (116.6–267.6)
Pain assessment (VAS), median (IQR) 39.5 (15.3–62.6) 43.0 (18.5–67.5)
UFS-QoL questionnaire
Symptom severity, median (IQR) 50.0 (37.5–62.5) 50.0 (37.5–62.5)
HRQL, median (IQR) 56.9 (42.2–75.9) 55.2 (41.4–71.6)
Note: BMI ¼ body mass index; HRQL ¼ health-related quality of life; IQR ¼ interquartile range; SD ¼ standard deviation; UFS-QoL ¼ uterine ﬁbroid symptom and health-related quality of life
questionnaire; VAS ¼ visual analogue scale (score range, 0–100, the higher the greater pain).
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and Supplemental Figure 3) progressively reduced from me-
dians of >200 at the start of the ﬁrst course to <100 after
the end of the second ulipristal acetate course in both treat-
ment groups (Table 2).
Fibroid volume. The median reductions in the combined vol-
ume of the three largest ﬁbroids from baseline to the period
after the ﬁrst menses at the end of treatment course 1 were
38% and 38%, and for treatment course 2, 54% and 58%
for patients receiving 5 and 10 mg of ulipristal acetate,
respectively (Table 2).
Pain and quality of life. Median visual analogue scale pain
scores for patients receiving 5 and 10 mg of ulipristal acetate
decreased substantially from baselines of 39.5 and 43.0,
respectively, to 6.0 (both treatment groups) at the end of
course 1 (Fig. 1A). There was some relative return of pain
when menstruation resumed during the off-treatment period
(median scores, 22.5 and 22.0) before decreasing again to me-
dians of 6.0 and 5.0 at the end of the second treatment course
for patients receiving 5 and 10 mg, respectively. Quality of
life was severely impaired at baseline (Fig. 1B and C), but
was substantially improved at the end of both treatment
courses for treatment groups. As with pain there was a partial
deterioration of quality of life during the off-treatment period
between treatment courses.
Surgery. Surgery was performed in only three and ﬁve pa-
tients receiving 5 and 10 mg of ulipristal acetate, respectively
(Appendix, available online).
General safety. The proportion of patients with adverse
events during the ﬁrst treatment course was the same (44%)
for both treatment groups (Table 3). Fewer patients reported
adverse events during the second treatment course (27%
and 30% for the 5- and 10-mg treatment groups, respec-
tively). Headaches and hot ﬂushes were the most frequently
reported adverse events, but occurred in %10% of patients,
and only one event of headache was reported as severe. Over-
all 21 (<5%) patients discontinued treatment at any time522during or after the two treatment courses due to adverse
events. There were 18 serious adverse events reported during
part I, 9 occurring during treatment and 9 occurring between
or after treatment courses (Table 3). The investigators assessed
only ﬁve serious adverse events (4 cases of menorrhagia and a
partial expulsion of a leiomyoma) as possibly related to uli-
pristal acetate therapy. No safety concerns were identiﬁed
from physical examination, vital signs, laboratory safety
tests, ovarian ultrasound, and electrocardiograms.
Endometrial safety. Transient increases in endometrial
thickness, assessed by transvaginal ultrasound, occurred in
less than 10% patients after each ulipristal acetate course
(Supplemental Table 4 in the Appendix, available online).
Some nonphysiological features, compatible with PAEC,
were reported by at least two pathologists for 17 biopsies
(8%) at screening in each treatment group, and for 29 (16%)
and 35 biopsies (19%) after treatment course 2 for the
5- and 10-mg treatment groups, respectively (Supplemental
Table 3 in the Appendix). Three cases of hyperplasia were
also reported, including one simple atypical endometrial hy-
perplasia that resolved into ‘‘benign secretory endometrium’’
by the end of treatment. The after treatment biopsy sample
from another patient was reported as endometrial adenocar-
cinoma by one of the three pathologists; however, adenocar-
cinoma was already observed by the same pathologist at the
initial biopsy (Table 3 and Appendix [available online]).
Laboratory Parameters
Laboratory results did not reveal any safety signals and no
patients discontinued treatment due to test abnormalities. A
table detailing the laboratory results can be found in
Supplemental Table 5 in the Appendix (available online).
DISCUSSION
The potential of long-term selective PR modulator treatment
to control bleeding, progressively shrink ﬁbroids, and enable
patients to avoid surgery was unknown. Due to uncertaintyVOL. 103 NO. 2 / FEBRUARY 2015
TABLE 2
Key efﬁcacy outcomes (full analysis set).
Variable
Ulipristal acetate
5 mg
(N[ 228)
Ulipristal acetate
10 mg
(N[ 223)
Difference (95% CI)
(ulipristal acetate
10 mg vs. 5 mg) P value
Primary end point
Amenorrhea at the end of both treatment courses (1 and 2), no./total no. (%) 122/197 (61.9) 136/187 (72.7) 10.8 (1.5–20.1) .03
Secondary end points
Controlled bleedinga at the end of both treatment courses (1 and 2), no./total no. (%) 150/185 (81.1) 148/172 (86.0) 5.0 (2.7 to 12.6) .26
Time to amenorrhea in course 1 (d), median (IQR) 5 (2–9) 4 (2–7)
Time to amenorrhea in course 2 (d), median (IQR) 5 (4–9) 6 (4–8)
PBAC (baseline actual), median (IQR) 224 (148–357) (N ¼ 218) 215 (151–373) (N ¼ 214)
After treatment course 1, median (IQR) 123 (45–313) (N ¼ 172) 129 (56–285) (N ¼ 156)
After treatment course 1 (CFB), median (IQR) 87 (167 to 13) (N ¼ 167) 85 (209 to 12) (N ¼ 151) 13 (54 to 28) .55
After treatment course 2, median (IQR) 92 (44–243) (N ¼ 159) 99 (37–202) (N ¼ 152)
After treatment course 2 (CFB), median (IQR) 95 (216 to 9) (N ¼ 152) 110 (236 to 50) (N ¼ 146) 28 (65 to 6) .10
Total volume of three largest ﬁbroids (cm3), baseline actual, median (IQR) 42.6 (24.0–94.2) 43.6 (27.3–117.3)
After ﬁrst menses after treatment course 1 (%CFB), median (IQR) 38.0 (60.3 to 14.3) (N ¼ 207) 38.2 (60.3 to 15.0) (N ¼ 206) 0.91 (0.80–1.03)b .15
End of treatment course 2 (%CFB), median (IQR) 54.1 (74.6 to 33.0) (N ¼ 197) 58.0 (74.1 to 36.3) (N ¼ 200) 0.89 (0.75–1.07)b .21
After ﬁrst menses after treatment course 2 (%CFB), median (IQR) 53.8 (77.1 to 23.4) (N ¼ 188) 58.1 (77.0 to 32.9) (N ¼ 192) 0.83 (0.69–1.01)b .06
Fibroid volume reductionR25%
After ﬁrst menses after treatment course 1, no./total no. (%) 129/207 (62.3) 137/206 (66.5) 4.2 (5.0 to 13.4) .43
End of treatment course 2, no./total no. (%) 158/197 (80.2) 166/200 (83.0) 2.8 (4.8 to 10.4) .56
After ﬁrst menses after treatment course 2, no./total no. (%) 139/188 (73.9) 152/192 (79.2) 5.2 (3.3 to 13.7) .28
Uterine volume (cm3), baseline actual, median (IQR) 176.9 (113.1–269.8) 175.2 (116.6–267.6)
After ﬁrst menses after treatment course 1 (%CFB), median (IQR) 13.3 (28.5 to 8.2) (N ¼ 214) 13.0 (29.5 to 3.5) (N ¼ 211) 0.99 (0.92–1.05)b .67
End of treatment course 2 (%CFB), median (IQR) 23.6 (40.9 to 4.4) (N ¼ 205) 25.5 (44.7 to 5.9) (N ¼ 203) 0.96 (0.88–1.04)b .32
After ﬁrst menses after treatment course 2 (%CFB), median (IQR) 20.38 (35.1 to 2.6) (N ¼ 194) 21.9 (41.5 to 0.4) (N ¼ 196) 0.95 (0.88–1.03)b .24
Uterine volume reductionR25%
After ﬁrst menses after treatment course 1, no./total no. (%) 63/214 (29.4) 66/211 (31.3) 1.8 (6.9 to 10.6) .76
End of treatment course 2, no./total no. (%) 98/205 (47.8) 103/203 (50.7) 2.9 (6.8 to 12.6) .62
After ﬁrst menses after treatment course 2, no./total no. (%) 90/194 (46.4) 90/196 (45.9) 0.5 (10.4 to 9.4) 1.00
Note: If a woman hadmore than three consecutivemissing days in the last 35 d of a treatment course the amenorrhea assessmentwas left asmissing, unless thewomen had reported bleeding during these last 35 d (subject is not in amenorrhea). Sensitivity analyses for end
point are reported in the Appendix, available online. %CFB ¼ percent change from baseline; CFB ¼ change from baseline; CI ¼ conﬁdence interval; IQR ¼ interquartile range; PBAC ¼ pictorial blood-loss assessment chart.
a Controlled bleeding was deﬁned as no episodes of heavy bleeding and a maximum of 8 d of bleeding during the last 56 d of a course of treatment.
b Ratio of ulipristal acetate 10 mg ratio to baseline to ulipristal acetate 5 mg ratio to baseline (95% CI).
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FIGURE 1
Effect of ulipristal acetate (UPA) on (A) pain, (B) symptom severity, and (C) health-related quality of life (QoL). (A) shows the ﬁbroid related pain using
a visual analogue scale (VAS) ranging from 0 (no pain) to 100 (worst possible pain). (B) shows the uterine ﬁbroid symptom severity consisting of a
validated questionnaire where lower scores indicate fewer symptoms. The symptom severity score comprises four domains: bleeding, abdominal
pressure, urination frequency, and fatigue. A level of 23 has been reported in a uterine ﬁbroid symptom and health-related quality of life
questionnaire (UFS-QoL) study for healthy subjects (34). (C) shows the health-related (HR) QoL where higher scores indicate a better QoL and
includes six domains: concern, activities, energy/mood, control, self consciousness, and sexual function. A level of 86 has been reported in a
UFS-QoL validation study as a reference for healthy subjects (34).
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ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEas to whether continuous selective PR modulator treatment
could lead to adverse consequence for the endometrium, a
model of intermittent treatment courses has been adopted.
In this randomized, double-blind study, we administered
two 12-week courses of ulipristal acetate (5 or 10 mg/d)
to patients with ﬁbroids and severe bleeding and evaluated
the efﬁcacy and safety during a period of about 10 months.
Baseline ﬁbroid volume and bleeding severity in the re-
cruited patients were similar to those reported for other clin-
ical studies (20, 21, 26). More than 90% of patients in each
group completed both ulipristal acetate treatment courses,
leading to a high level of conﬁdence in interpretation of
the results.
Both dose regimens of ulipristal acetate controlled the
most debilitating symptom of ﬁbroids (menorrhagia) as evi-
denced by the high proportion of patients with amenorrhea
at the end of each treatment course. Rates of amenorrhea
were approximately 10% more for the 10-mg dose compared
with the 5-mg dose regimen, but even with the 5-mg dose
more than 80% patients achieved controlled bleeding at the
end of both treatment courses. This leads us to conclude
that the 5-mg dose approved for preoperative use should be
considered for future long-term symptom management. As524expected, menstruation resumed after each treatment course
but the magnitude of menstrual bleeding progressively
diminished during the off-treatment periods to a median level
below the threshold for menorrhagia.
Both doses of ulipristal acetate were effective in shrinking
ﬁbroids, more than halving the ﬁbroid volume in more than
50% of patients by the end of the second treatment course.
Patients also reported substantial improvements in pain and
quality of life during treatment, and these improvements
were partly maintained during the off-treatment period.
Very few patients (<2%) discontinued the study to undergo
surgery.
Most adverse events were mild or moderate and
occurred less frequently in the second treatment course.
Four serious adverse events considered related to ulipristal
acetate by the investigator were cases of menorrhagia (all
occurring off-treatment when menstruation was expected
to resume). This incidence is not more than reported in
previous studies of ulipristal acetate, placebo, and compar-
ator agents in women with ﬁbroid-related menorrhagia
(20, 21, 26). The only other serious adverse event
considered related to ulipristal acetate was a partial
expulsion of a leiomyoma.VOL. 103 NO. 2 / FEBRUARY 2015
TABLE 3
Adverse events (safety set).
Type
Treatment course 1 Treatment course 2
ulipristal acetate
5 mg
(N[ 230)
ulipristal acetate
10 mg
(N[ 221)
ulipristal acetate
5 mg
(N[ 215)
ulipristal acetate
10 mg
(N[ 205)
N % N % N % N %
On-treatment AE leading to study withdrawala 6 2.6 7 3.2 1 0.5 4 2.0
Off-treatment AE leading to study withdrawalb 2 0.9 1 0.5 0 0 0 0
At least one on-treatment AEa 102 44.3 98 44.3 59 27.4 61 29.8
Headache 21 9.1 23 10.4 13 6.0 5 2.4
Hot ﬂush 13 5.7 15 6.8 8 3.7 6 2.9
Breast pain/tenderness/discomfort 7 3.0 5 2.3 2 0.9 0 0
Inﬂuenza 9 3.9 8 3.6 0 0 1 0.5
Nasopharyngitis 2 0.9 8 3.6 3 1.4 1 0.5
Nausea 8 3.5 4 1.8 0 0 0 0
Fatigue 3 1.3 7 3.2 3 1.4 2 1.0
At least one off-treatment AEb 37 16.1 42 19.0 25 11.6 22 10.7
Headache 6 2.6 8 3.6 1 0.5 2 1.0
At least one on-treatment SAEa 3 1.3 3 1.4 1 0.5 2 1.0
Anemia 1 0.4 0 0 0 0 0 0
Arteriospasm coronary 0 0 1 0.5 0 0 0 0
Tinnitus 0 0 1 0.5 0 0 0 0
Cholelithiasis 0 0 1 0.5 0 0 0 0
Periarthritis 1 0.4 0 0 0 0 0 0
Bipolar disorder (same subject) 1 0.4 0 0 1 0.5 0 0
Breast cancer 0 0 0 0 0 0 1 0.5
Menorrhagia 0 0 0 0 0 0 1 0.5
At least one off-treatment SAEb 5 2.2 3 1.4 1 0.5 0 0
Menorrhagia 4 1.7 0 0 0 0 0 0
Castleman's disease 1 0.4 0 0 0 0 0 0
Partial expulsion of uterine myoma 0 0 1 0.5 0 0 0 0
Small intestinal obstruction 0 0 1 0.5 0 0 0 0
Carpal tunnel syndrome 0 0 1 0.5 0 0 0 0
Endometrial adenocarcinomac 0 0 0 0 1 0.5 0 0
Note: Table includes adverse events (AEs) occurring inR3% patients as well as all serious adverse events (SEA) occurring at or after the ﬁrst dose of study drug and on or before the last visit after
treatment course 2. Patients could have more than one AE of same type.
a On-treatment Treatment Emergent Adverse Events (TEAEs) are deﬁned as events whose start date is during or after the ﬁrst dose of study drug, up to and including 7 days after the last dose of
study medication within each treatment course.
b Off-treatment TEAEs are deﬁned as events whose start date is more than 7 d after the last dose of studymedicationwithin each treatment course and before the start of the next treatment course.
c Preexisting condition: On initial and follow-up biopsy, one of three pathologists reported presence of adenocarcinoma. Further details the Appendix, available online.
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Fertility and Sterility®Donnez et al. (20, 21) previously reported that a 3-month
course of ulipristal acetate induces PAEC in approximately
60% of patients and that this is fully reversible 6 months after
the end of treatment. In the present study the endometrium
was biopsied approximately 6 weeks after the end of the sec-
ond course of ulipristal acetate, and nonphysiological features
were observed in approximately 16% and 19% patients who
had been treated with 5 and 10 mg of ulipristal acetate,
respectively. Thus repeated courses of ulipristal acetate do
not increase the frequency of PAEC. The incidence of endome-
trial hyperplasia after two treatment courses was <1%, which
is consistent with the expected frequency in women with
abnormal uterus bleeding within this age range (31).
Currently there are no approved long-term medical treat-
ment options for the management of patients with symptom-
atic ﬁbroids. The GnRH agonists with hormonal add-back
therapy (9, 32, 33, 35, 36), oral progestins (alone), and
intrauterine levonorgestrel (37–41) have been used but are
associated with various tolerability and safety issues and
inconsistent or lack of efﬁcacy in shrinking ﬁbroids. To be
acceptable as a long-term management option, medicalVOL. 103 NO. 2 / FEBRUARY 2015therapy should rapidly control bleeding and progressively
shrink the ﬁbroids, in addition to showing a good safety pro-
ﬁle. If medical treatment has to be intermittent, then the
regimen must be simple, and there should not be regrowth
of ﬁbroids and return of symptoms during off-treatment pe-
riods. We believe that the intermittent 12-week ulipristal ac-
etate daily dose regimens (the ﬁrst course to be administered
at the start of a menstrual cycle, and subsequent courses to
commence at the start of the second menses after the previous
course) fulﬁll most of these criteria, as evidenced by the low
side effect burden and discontinuation rate, and the high
compliance with treatment. Some patients did experience
pain and excessive bleeding during off-treatment periods
but generally not of the samemagnitude as prior to treatment.
Also there was no regrowth of ﬁbroids observed during
follow-up. Thus our results suggest that intermittent ulipristal
acetate is a viable and attractive long-term medical manage-
ment option for patients with symptomatic ﬁbroids. Our data
are also consistent with the results of an earlier study (26) re-
porting that up to four intermittent treatment courses of uli-
pristal acetate could be successively administered to control525
ORIGINAL ARTICLE: GYNECOLOGY AND MENOPAUSEbleeding and shrink ﬁbroids. However, interpretation of the
results of that study was limited by the open-label design
with only one dose (10 mg not currently approved), the
limited sample size, and by the inclusion of subjects desiring
only a single course of treatment before surgery, leading to a
substantial decrease in numbers of patients progressing to the
second treatment course.
There are some weaknesses in our study.We could not use
a placebo control for long-term ulipristal acetate treatment.
However, we previously demonstrated that a 3-month course
of ulipristal acetate was superior to placebo and not inferior to
a GnRH agonist for control of uterine bleeding (21–26).
Although our study showed an advantage of the 10-mg
dose for rates of amenorrhea, bleeding control was compara-
ble with the 5-mg dose.
We report results for only two treatment courses, but
further intermittent treatment courses have been reported as
effective (26). We did not recruit many women of African
origin, but previous short-term studies have reported efﬁcacy
in these patients (18, 19).
In conclusion, in this large double-blind, randomized
study, we showed that repeated 12-week courses of oral uli-
pristal acetate (5 and 10 mg/d) effectively and safely control
bleeding and pain, reduce ﬁbroid volume, and restore quality
of life in patients with symptomatic ﬁbroids. Compliance with
intermittent treatment is good, and symptomatic improve-
ment and ﬁbroid volume shrinkage can be largely maintained
during the off-treatment periods.
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SUPPLEMENTAL FIGURE 1
Schedule of treatments and visits.
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SUPPLEMENTAL FIGURE 2
Patient disposition. Withdrawals are presented according to the timeframes in which they occurred, either during treatment or after treatment
completion for each course. Two subjects randomized to the ulipristal acetate 10 mg group received ulipristal acetate 5 mg treatment in error;
these subjects are included in the FAS Sets according to randomization, and in the Safety Set according to treatment received.
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SUPPLEMENTAL FIGURE 3
Pictoral BleedingAssessment Chart recording document. PBAC is one of the current standardmethods used to objectively estimatemenstrual blood
loss and diagnose menorrhagia. The method which was developed and validated by Higham and Janssen deﬁnes excessive bleeding as a PBAC
score >100.
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